FilingReader Intelligence
Zelgen wins approval for cancer drug trial
August 20, 2025 at 08:50 AM UTC•By FilingReader AI
Suzhou Zelgen Biopharmaceuticals received approval from China's National Medical Products Administration for clinical trials of its ZG005 injection combined with gicacixitine hydrochloride tablets and chemotherapy for advanced solid tumors.
ZG005 is a PD-1/TIGIT bispecific antibody, while gicacixitine hydrochloride is a JAK and ACVR1 dual inhibitor. The approval was granted on June 13, 2025.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SSE:688266•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Suzhou Zelgen Biopharmaceuticals publishes news
Free account required • Unsubscribe anytime